Noroviruses, particularly GII.4 strains, undergo rapid antigenic variation in key surface-exposed residues to escape human herd immunity, complicating the development of effective vaccines.
Noroviruses Represent a Significant Worldwide Disease Burden Noroviruses (NoVs), members of the Calicivirus family, are small, positive-polarity RNA viruses and the most important cause of human foodborne viral gastroenteritis worldwide. These viruses cause gastrointestinal disease, resulting in recurrent bouts of vomiting and diarrhea that typically last 24-48 hours. NoVs are transmitted via the fecal-oral route, most commonly through infected food or water or person-to-person contact, and result in 267 million infections 1 and over 200,000 deaths each year, mostly in infants and the elderly Vaccines and therapeutics are under development but face considerable challenges as there is no cell-culture system or small-animal model for human disease, and these viruses are highly heterogeneous and undergo antigenic variation in response to human herd immunity, further complicating our understanding of the complex immune interactions that regulate susceptibility and disease.
Debbink et al. (Thu,) conducted a review in Norovirus infection. Norovirus vaccines and therapeutics was evaluated. Noroviruses, particularly GII.4 strains, undergo rapid antigenic variation in key surface-exposed residues to escape human herd immunity, complicating the development of effective vaccines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: